Immunocompromise and durability of BNT162b2 vaccine against severe outcomes due to omicron and delta variants-Reference-Cited by-同舟云学术

Immunocompromise and durability of BNT162b2 vaccine against severe outcomes due to omicron and delta variants

Published:2022-07 Issue:7 Volume:10 Page:e61-e62
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Tartof Sara Y,Slezak Jeff M,Puzniak Laura,Hong Vennis,Xie Fagen,Ackerson Bradley K,Valluri Srinivas R,Jodar Luis,McLaughlin John M.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference6 articles.

1. Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test negative case–control study;Tartof;Lancet Respir Med,2022

2. Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: a retrospective cohort study;Tartof;Lancet Reg Health Am,2022

3. Duration of mRNA vaccine protection against SARS-CoV-2 omicron BA.1 and BA.2 subvariants in Qatar;Chemaitelly;medRxiv,2022

4. Protection by a fourth dose of BNT162b2 against omicron in Israel;Bar-On;N Engl J Med,2022

5. Fourth dose of BNT162b2 mRNA COVID-19 vaccine in a nationwide setting;Magen;N Engl J Med,2022

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nasopharyngeal specific selection and emergence of SARS-CoV-2 spike fusion peptide mutation P812S during chronic infection;2024-09-06

2. No more government-imposed societal-level COVID-19 control measures but still significant self-experienced burden for severely immunocompromised individuals – A cross-sectional survey in the Netherlands;Preventive Medicine Reports;2024-09

3. Risk Factors for Recurrent Urinary Tract Infections Among Women in a Large Integrated Health Care Organization in the United States;The Journal of Infectious Diseases;2024-06-28

4. Effectiveness of COVID-19 mRNA vaccine in preventing infection against Omicron strain: Findings from the Hiroshima Prefecture COVID-19 version J-SPEED for PCR center;PLOS Global Public Health;2024-04-17

5. Durability of protection from original monovalent and bivalent COVID-19 vaccines against COVID-19-associated hospitalization and severe in-hospital outcomes among adults in the United States — September 2022–August 2023;2024-01-09